MCID: NRT001
MIFTS: 53

Neurotic Disorder

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Neurotic Disorder

MalaCards integrated aliases for Neurotic Disorder:

Name: Neurotic Disorder 12 15 17
Adjustment Disorders 43 71 32
Neurosis 12 36 15
Reactive Depression 12 71
Neurotic Disorders 43 71
Neurotic Depression Reactive Type 12
Neurotic Depressive State 12
Depression, Neurotic 71
Depressive Neurosis 12
Neurotic Depression 12
Depressive Disorder 71
Psychoneurosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4964
KEGG 36 H01671
SNOMED-CT 67 78667006 87414006
UMLS 71 C0001546 C0011579 C0011581 more

Summaries for Neurotic Disorder

KEGG : 36 Neurosis is a class of functional mental disorders involving distress but neither delusions nor hallucinations, whereby behavior is not outside socially acceptable norms. The state of research on neurosis has moved towards looking at biological and genetic substrates or mechanisms underlying neurosis. The recent literature shows acceptance of common mental disorders such as Generalized anxiety disorder (GAD), Panic disorder (PD), and Obsessive-compulsive disorder (OCD), across cultures replacing neurotic disorder. Usage of the diagnosis of neurosis has been decreased, and replaced by newer categories in the current popular classificatory systems. In the International Classification of Diseases (ICD-10), all disorders regarded as neurosis remained together but under the division of rubric 'neurotic, stress-related and somatoform disorders'. In the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), neurosis has been eliminated as a category.

MalaCards based summary : Neurotic Disorder, also known as adjustment disorders, is related to dissociative disorder and somatization disorder, and has symptoms including depressed reaction and depressed - symptom. An important gene associated with Neurotic Disorder is MFSD8 (Major Facilitator Superfamily Domain Containing 8), and among its related pathways/superpathways are Neuroactive ligand-receptor interaction and Dopaminergic synapse. The drugs Acetylcholine and Valsartan have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are behavior/neurological and nervous system

Disease Ontology : 12 An anxiety disorder that involves discress but neither delusions nor hallucinations.

Wikipedia : 74 Neurosis is a class of functional mental disorders involving chronic distress but neither delusions nor... more...

Related Diseases for Neurotic Disorder

Diseases related to Neurotic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 293)
# Related Disease Score Top Affiliating Genes
1 dissociative disorder 30.7 SLC6A4 HTR2A FLNA
2 somatization disorder 30.3 SLC6A4 HTR2A HTR1A
3 acute stress disorder 30.2 SLC6A4 MFSD8 BDNF
4 body dysmorphic disorder 30.1 SLC6A4 MAOA HTR2A
5 obsessive-compulsive personality disorder 30.1 SLC6A4 HTR2A
6 social phobia 30.1 SLC6A4 MAOA HTR1A
7 premenstrual tension 29.9 LIPN HTR1A
8 tic disorder 29.9 SLC6A4 MAOA HTR2A
9 hypochondriasis 29.9 SLC6A4 HTR2A HTR1A BDNF
10 eating disorder 29.8 SLC6A4 HTR2A BDNF
11 dysthymic disorder 29.8 SLC6A4 MAOA HTR2A HTR1A BDNF
12 panic disorder 29.8 SLC6A4 MAOA HTR2A HTR1A BDNF
13 adjustment disorder 29.8 SLC6A4 HTR2A FLNA BDNF
14 alexithymia 29.7 SLC6A4 IL6 HTR1A
15 delusional disorder 29.6 TH MFSD8 HTR2A HTR1A
16 alcohol use disorder 29.6 SLC6A4 HTR2A HTR1A BDNF
17 generalized anxiety disorder 29.6 SLC6A4 MAOA HTR2A HTR1A BDNF
18 agoraphobia 29.6 SLC6A4 MAOA HTR2A HTR1A
19 post-traumatic stress disorder 29.6 SLC6A4 MAOA HTR2A BDNF
20 antisocial personality disorder 29.4 SLC6A4 MAOA HTR2A
21 personality disorder 29.4 TH SLC6A4 MAOA HTR2A HTR1A BDNF
22 depression 29.4 SLC6A4 MAOA HTR2A HTR1A BDNF
23 melancholia 29.3 SLC6A4 MAOA HTR2A HTR1A BDNF
24 atypical depressive disorder 29.3 SLC6A4 MAOA HTR2A HTR1A BDNF
25 alcohol dependence 29.1 TH SLC6A4 MAOA HTR2A HTR1A BDNF
26 obsessive-compulsive disorder 29.0 SLC6A4 MAOA IL6 HTR2A HTR1A BDNF
27 dementia 28.8 TH MAOA HTR2A HTR1A BDNF
28 borderline personality disorder 28.8 TH SLC6A4 MAOA HTR2A HTR1A BDNF
29 narcolepsy 28.7 SLC6A4 MAOA IL6 HTR2A BDNF
30 major depressive disorder 28.6 SLC6A4 MAOA IL6 HTR2A HTR1A BDNF
31 paranoid schizophrenia 28.6 SLC6A4 MAOA IL6 HTR2A HTR1A BDNF
32 mental depression 28.6 SLC6A4 MAOA IL6 HTR2A HTR1A BDNF
33 psychotic disorder 28.5 TH SLC6A4 MAOA HTR2A HTR1A BDNF
34 substance abuse 28.4 SLC6A4 MAOA INS HTR2A HTR1A BDNF
35 schizoaffective disorder 28.4 SLC6A4 INS HTR2A HTR1A BDNF
36 autism 28.3 TH SLC6A4 MAOA HTR2A HTR1A BDNF
37 anorexia nervosa 28.2 SLC6A4 MAOA INS HTR2A HTR1A BDNF
38 fibromyalgia 28.1 SLC6A4 INS IL6 HTR2A BDNF
39 body mass index quantitative trait locus 11 28.0 MAOA INS IL6 HTR2A HTR1A BDNF
40 chronic fatigue syndrome 28.0 SLC6A4 MAOA INS IL6 HTR2A HTR1A
41 mood disorder 28.0 TH SLC6A4 MAOA IL6 HTR2A HTR1A
42 bipolar disorder 27.9 TH SLC6A4 MAOA IL6 HTR2A HTR1A
43 hypertension, essential 27.6 TH SLC6A4 INS IL6 HTR2A FLNA
44 sleep disorder 27.4 TH SLC6A4 INS IL6 HTR2A HTR1A
45 anxiety 27.4 TH SLC6A4 MAOA INS IL6 HTR2A
46 migraine with or without aura 1 27.3 SLC6A4 MAOA LIPN INS IL6 HTR2A
47 schizophrenia 27.3 TH SLC6A4 MAOA INS IL6 HTR2A
48 disease of mental health 27.0 TH SLC6A4 MAOA INS IL6 HTR2A
49 endogenous depression 27.0 TH SLC6A4 MAOA INS IL6 HTR2A
50 panic disorder 1 11.7

Graphical network of the top 20 diseases related to Neurotic Disorder:



Diseases related to Neurotic Disorder

Symptoms & Phenotypes for Neurotic Disorder

UMLS symptoms related to Neurotic Disorder:


depressed reaction, depressed - symptom

MGI Mouse Phenotypes related to Neurotic Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.73 BDNF FLNA GAN GPX4 HTR1A HTR2A
2 nervous system MP:0003631 9.36 BDNF FLNA GAN GPX4 HTR1A IL6

Drugs & Therapeutics for Neurotic Disorder

Drugs for Neurotic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 612)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
2
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
3
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 497540 5095
4
Reboxetine Approved, Experimental Phase 4 98769-81-4, 71620-89-8 123628 65856
5
Cycloserine Approved Phase 4 68-41-7 401 6234
6
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
7
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
8
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
9
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
10
Brexpiprazole Approved, Investigational Phase 4 913611-97-9 11978813
11
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
12
Amitriptyline Approved Phase 4 50-48-6 2160
13
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
14
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
15
Propranolol Approved, Investigational Phase 4 525-66-6 4946
16
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
17
Desipramine Approved, Investigational Phase 4 50-47-5 2995
18
Methyltestosterone Approved Phase 4 58-18-4 6010
19
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
20
Testosterone enanthate Approved Phase 4 315-37-7 9416
21
Moclobemide Approved, Investigational Phase 4 71320-77-9 4235
22
Memantine Approved, Investigational Phase 4 19982-08-2 4054
23
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
24
Ziprasidone Approved Phase 4 146939-27-7 60854
25
Iloperidone Approved Phase 4 133454-47-4 71360
26
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
27
Prazosin Approved Phase 4 19216-56-9 4893
28
Terazosin Approved Phase 4 63590-64-7 5401
29
Zolpidem Approved Phase 4 82626-48-0 5732
30
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
31
Calcium carbonate Approved, Investigational Phase 4 471-34-1
32
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
33
Methohexital Approved Phase 4 151-83-7 9034
34
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
35
Methadone Approved Phase 4 76-99-3 4095
36
Ribavirin Approved Phase 4 36791-04-5 37542
37
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
38
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
39
Topiramate Approved Phase 4 97240-79-4 5284627
40
Doxepin Approved, Investigational Phase 4 1668-19-5 667477 667468
41
Protriptyline Approved Phase 4 438-60-8 4976
42
Isocarboxazid Approved Phase 4 59-63-2 3759
43
Trimipramine Approved Phase 4 739-71-9 5584 4055
44
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
45
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
46
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
47
Donepezil Approved Phase 4 120014-06-4 3152
48
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
49
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
50
Levomilnacipran Approved, Investigational Phase 4 96847-54-0

Interventional clinical trials:

(show top 50) (show all 4118)
# Name Status NCT ID Phase Drugs
1 Phase 4 Study of Escitalopram Treatment and Biomarkers in Major Depressive Disorder Unknown status NCT01997580 Phase 4 escitalopram
2 The Effect and Reliability of Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders Unknown status NCT03122158 Phase 4 Escitalopram
3 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Unknown status NCT02294305 Phase 4 Vortioxetine;Placebo
4 Role of Inflammation Factors and Insulin Resistance in the Pathophysiology and Treatment Response of Major Depressive Disorder Unknown status NCT01699490 Phase 4 Fluoxetine + Valsartan;Fluoxetine + Placebo
5 Pharmacogenomics Studies of Antidepressants Unknown status NCT01204086 Phase 4 Venlafaxine;Fluoxetine
6 Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder Unknown status NCT02051413 Phase 4 Venlafaxine extended release
7 Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder Unknown status NCT01460212 Phase 4 SSRI antidepressants
8 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
9 Dose Response Effects of Estrogen Augmentation in Mood & Memory in Perimenopausal Depression Unknown status NCT00229450 Phase 4 estrogen
10 Clinical Trial of the Use of Ketamine in Treatment Resistant Depression Unknown status NCT02610712 Phase 4 Ketamine
11 Phase 4 Study on the Effect of Partial Sleep Deprivation on Cognition and the IL-6-gp130-System in Individuals With Major Depression Unknown status NCT00291239 Phase 4
12 Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder Unknown status NCT00442481 Phase 4 Escitalopram
13 Effect of Escitalopram vs. Reboxetine on Somatic and Visceral Sensitivity of Patients With Major Depressive Disorder: a Randomized, Double Blind Clinical Trial Unknown status NCT00209807 Phase 4 escitalopram;Reboxetine
14 A Dimensional Approach to Evaluate Reward Processing in Major Depressive Disorder Before and After Treatment With Desvenlafaxine Unknown status NCT02859103 Phase 4 Desvenlafaxine
15 Turgut Ozal Medical Center Department of Anesthesiology and Reanimation Unknown status NCT02267980 Phase 4 Sevoflurane;Ketamine;Saline
16 Inflammatory Markers and Cognitive Function in Major Depression:a Pilot Study Unknown status NCT01391221 Phase 4 Duloxetine
17 Exploring Alterations of Central Autonomic Modulation in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4 Quetiapine
18 Duloxetine for the Treatment of Major Depression in Midlife Women: Effects on Brain Structure and Functioning, Mood, and Quality of Life Unknown status NCT00889369 Phase 4 Duloxetine
19 Hyperventilation and ECT Seizure Duration: Effects on Cerebral Oxygen Saturation, and Therapeutic Outcome With Comparisons Between Etomidate and Ketamine in Patients With Major Depressive Disorder Unknown status NCT02924090 Phase 4 Etomidate;Ketamine
20 A Randomised Trial Investigating the Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder. Unknown status NCT01483053 Phase 4 Agomelatine;Escitalopram
21 Algorithm Guided Treatment Strategies for Major Depressive Disorder Unknown status NCT01764867 Phase 4 Escitalopram;Mirtazapine;Fluoxetine;Citalopram;Escitalopram;Paroxetine;Sertraline;Fluvoxamine;Venlafaxine;Duloxetine;Mirtazapine;Bupropion;Trazodone
22 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar I and II Depression. Unknown status NCT00335205 Phase 4 ropinirole
23 White Matter Structure and Response to Treatment With Antidepressants: a Study of Desvenlafaxine in Major Depression. A Pilot Study Unknown status NCT01492621 Phase 4 Desvenlafaxine
24 Escitalopram Treatment of Major Depression in Diabetes Mellitus: An Open Label Unknown status NCT00650897 Phase 4 Escitalopram
25 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
26 Evaluation of the Efficacy of Repetitive Transcranial Magnetic Stimulation on Cognitive, Anxiety and Depressive Symptoms in Patients Diagnosed With Major Depressive Disorder Unknown status NCT02213016 Phase 4
27 THE AIUNI - Integral Assessment in Unipolar Depression Unknown status NCT02268487 Phase 4 Sertraline
28 A Randomized Controlled Study Comparing Fluoxetine With Bupropion for Impulsivity and Suicidality in Patients With Major Depressive Disorder and Comorbid Alcoholism (Abuse or Dependence) Unknown status NCT00449007 Phase 4 fluoxetine;bupropion
29 Exploratory Study to Assess the Efficacy of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4 Escitalopram
30 Behandlung Von Leichten Und Unterschwelligen Depressionen. Eine Randomisierte, Kontrollierte Studie Zum Wirksamkeitsnachweis Eines Serotonin-Wiederaufnahme-Hemmers (SSRI), Einer Kognitiven Verhaltenstherapie Und Einer Freien Therapiewahl ("Treatment of Mild and Subthreshold Depressive Disorders". A Randomized, Controlled Trial on the Efficacy of a Serotonin-Reuptake-Inhibitor (SSRI), a Cognitive-Behavioral Therapy and of Free Choice Between SSRI and CBT") Unknown status NCT00226642 Phase 4 Sertralin;Placebo
31 Sequence Towards Remission in Depression Unknown status NCT01628783 Phase 4 escitalopram 10 mg;Placebo
32 A Comparative Trial of TMS Approaches to Treating Depression Unknown status NCT01906905 Phase 4
33 Brain Mechanisms and Targeting Insomnia in Major Depression Unknown status NCT00628914 Phase 4 escitalopram and eszopiclone;Escitalopram, eszopiclone, and placebo;Escitalopram
34 Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy - a Monocentric, Double-Blind, Placebo-Controlled Trial Unknown status NCT00150839 Phase 4 Mirtazapine;Venlafaxine
35 Neurochemical,Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder Unknown status NCT02346682 Phase 4 venlafaxine
36 Antidepressant Treatments During Pregnancy and Lactation: Prediction of Drug Exposure Through Breastfeeding and Evaluation of Drug Effect on the Neonatal Adaptation and the Development of the Young Child Unknown status NCT01796132 Phase 4 SSRI/SNRI
37 A Double-Blind, Placebo-Controlled Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
38 TMSFOS: Preliminary Study to Investigate the Effect of rTMS and SSRI Antidepressants on Leukocyte Expression of the C-FOS and DUSP1 Genes in Patients Treated for Depression Unknown status NCT02042573 Phase 4 SSRI (SEROPLEX ou ZOLOFT)
39 Treatment Prediction in Adolescent and Adult Depression Unknown status NCT00106197 Phase 4 Bupropion
40 a Randomized, Double Blind, Placebo-controlled, Multicenter Clinical Trial of Efficacy and Safety of Shu Gan yi Yang Capsule in the Treatment of Depression Associated With Erectile Dysfunction (Stagnation of Liver qi and Kidney Deficiency) Unknown status NCT03290313 Phase 4 shu gan yi yang capsule;shu gan yi yang capsule simulation agent
41 A Double-Blind, Placebo-Controlled, Enriched Enrollment Randomized Withdrawal Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis Unknown status NCT01329406 Phase 4 Milnacipran;Placebo
42 Prediction of Individual Treatment Response Based on Brain Changes at the Early Phase of Antidepressant Treatment in Major Depressive Disorder Using Machine Learning Classification Analysis Unknown status NCT02330679 Phase 4 Desvenlafaxine;Placebo
43 A Randomized Controlled Trial of Antidepressant Maintenance for Major Depression Following Mild Traumatic Brain Injury Unknown status NCT00162916 Phase 4 citalopram;Placebo
44 Collaborative Care for Depressed Elders in China Unknown status NCT01287494 Phase 4 Sertraline
45 A Multicenter, Double Blind Trial to Compare the Efficacy and Safety of Escitalopram With Placebo in Patients With Acute Stroke for the Prevention of Poststroke Depression and Related Symptoms (Emotional Incontinence, Anger Proneness), and for Improvement of Neurologic, Cognitive Function and Quality of Life Unknown status NCT01278498 Phase 4 Escitalopram;sugar pill
46 Phase 4 Study of Vitamin D3 Supplementation for Outcomes in Patients With Unipolar Depression Unknown status NCT01390662 Phase 4
47 Group Mindfulness-Based Cognitive Therapy for the Treatment of Late-Life Depression and Anxiety Symptoms in Primary Care: A Randomized Controlled Trial Unknown status NCT02777905 Phase 4
48 A Controlled Study of the Efficacy of Botulinum Toxin A (Botox) for the Treatment of Major Depressive Disorder (MDD) Unknown status NCT01556971 Phase 4 Botox;Saline Solution
49 Phase 3 Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study Unknown status NCT00426946 Phase 4 Reboxetine
50 Prospective 24-week Study, Comparing Clinical Outcomes Between Switching Antidepressants and Maintaining the Same Antidepressant in Patients With Major Depressive Disorder Who do Not Show a 20% Reduction in Symptoms at Week 2 Unknown status NCT00519012 Phase 4 Sertraline to Paroxetine;Paroxetine to Sertraline

Search NIH Clinical Center for Neurotic Disorder

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Alprazolam
Amitriptyline
Amitriptyline Hydrochloride
Amoxapine
Bupropion
Bupropion hydrobromide
Bupropion Hydrochloride
Buspirone
buspirone hydrochloride
Citalopram
Citalopram hydrobromide
Clomipramine
Clomipramine Hydrochloride
Desipramine
Desipramine Hydrochloride
Doxepin
Doxepin Hydrochloride
Escitalopram
Escitalopram oxalate
Fluoxetine
Fluoxetine Hydrochloride
Fluvoxamine
Fluvoxamine Maleate
HYPERICUM PERFORATUM (ST. JOHN'S WORT)
Imipramine
Imipramine Hydrochloride
Imipramine pamoate
Isocarboxazid
Isoflurane
Kava preparation
Lithium
Lithium Aspartate
Lithium Carbonate
lithium citrate
Lorazepam
Maprotiline
Maprotiline Hydrochloride
Methylphenidate
Methylphenidate Hydrochloride
Mirtazapine
nefazodone
Nortriptyline
Nortriptyline Hydrochloride
Paroxetine
Paroxetine Hydrochloride
Phenelzine
Phenelzine Sulfate
Pramipexole
Pramipexole dihydrochloride
Protriptyline
Protriptyline Hydrochloride
Selegiline
selegiline hydrochloride
Sertraline
Sertraline Hydrochloride
Temazepam
Tranylcypromine
Tranylcypromine sulfate
Trazodone
Trazodone Hydrochloride
Tricyclic Antidepressant [EPC]
Trimipramine
Trimipramine Maleate
venlafaxine
Venlafaxine hydrochloride

Cochrane evidence based reviews: adjustment disorders

Genetic Tests for Neurotic Disorder

Anatomical Context for Neurotic Disorder

MalaCards organs/tissues related to Neurotic Disorder:

40
Brain, Testes, Heart, Cortex, Breast, Prefrontal Cortex, Eye

Publications for Neurotic Disorder

Articles related to Neurotic Disorder:

(show top 50) (show all 4552)
# Title Authors PMID Year
1
Triptolide-induced hepatotoxicity via apoptosis and autophagy in zebrafish. 61
31321794 2019
2
Can Anything Good Ever Come From Bearing Migraine Attacks? Suggestions for a Comprehensive Concept of Gain in Migraine. 61
31734850 2019
3
The Wolf Man's Glückshaube: Rereading Sergei Pankejeff's Memoir. 61
31850786 2019
4
Somatic symptoms and their association with anxiety and depression in Chinese patients with cardiac neurosis. 61
31448660 2019
5
Clinical Role of Aspirin in Mood Disorders: A Systematic Review. 61
31671812 2019
6
Differentiating Psychosomatic, Somatopsychic, Multisystem Illnesses, and Medical Uncertainty. 61
31597359 2019
7
Inventing the enemy. 61
31418830 2019
8
Insanity: A Legal and Cinematic Diagnosis. 61
31033643 2019
9
The uses of trauma in experiment: Traumatic stress and the history of experimental neurosis, c. 1925-1975. 61
31829295 2019
10
[The energy metaphor for the human body and its effect on the rise of neurasthenia, neurosis and depression]. 61
31531581 2019
11
Effectiveness of the traditional Japanese Kampo medicine Yokukansan for chronic migraine: A case report. 61
31490382 2019
12
Traumatic Hystero-Neurasthenia in Professor Charcot's Leçons du Mardi. 61
31464991 2019
13
Rudolf Allers' conception of neurosis as a metaphysical conflict. 61
31544537 2019
14
Premature mortality of people with personality disorder in the Nottingham Study of Neurotic Disorder. 61
31414571 2019
15
Construction of Disease Similarity Networks Using Concept Embedding and Ontology. 61
31437962 2019
16
Between Shell Shock and PTSD? 'Accident Neurosis' and Its Sequelae in Post-War Britain. 61
31384101 2019
17
Sex dimorphism in the distribution of adipose tissue and its influence on proinflammatory adipokines and cardiometabolic profiles in motor complete spinal cord injury. 61
29465306 2019
18
Prescribing Prevalence, Effectiveness, and Mental Health Safety of Smoking Cessation Medicines in Patients With Mental Disorders. 61
31289809 2019
19
Factors associated with long-term prescription of benzodiazepine: a retrospective cohort study using a health insurance database in Japan. 61
31350250 2019
20
A Psychoanalytical Approach to Diogenes Syndrome. 61
31090506 2019
21
Neuro-Cognition in Adolescents with Dissociative Disorder: A Study from a Tertiary Care Center of North India. 61
31142926 2019
22
Historical perspectives on evolving operational definitions of concussive brain injury: From railway spine to sport-related concussion. 61
31146639 2019
23
Increased cerebrospinal fluid neurofilament light chain in central nervous system inflammatory demyelinating disease. 61
30771578 2019
24
Ménière's disease with unremitting floating sensation is associated with canal paresis, gravity-sensitive dysfunction, mental illness, and bilaterality. 61
30072163 2019
25
Suicide attempts by drug overdose at Jichi Medical University Hospital emergency centre: A study of patient characteristics and quantity of drug overdose. 61
30318306 2019
26
The impact of inhaled bronchodilators on bronchopulmonary dysplasia: a nonrandomized comparison from the NEuroSIS trial. 61
30922128 2019
27
Neurosis and true dermatosis: a case of ossified pilomatricoma developing within a self-inflicted ulcer. 61
30865412 2019
28
A descriptive epidemiological study of disability prevalence attributed to neurotic disorders in China. 61
30611025 2019
29
Effect of Yokukansan and Yokukansankachimpihange on Aggressive Behavior, 5-HT Receptors and Arginine Vasopressin Expression in Social Isolation-Reared Mice. 61
31787717 2019
30
A Systematic Review of the Effect of Probiotic Supplementation on Schizophrenia Symptoms. 61
30947230 2019
31
Polydatin Attenuates Neuronal Loss via Reducing Neuroinflammation and Oxidative Stress in Rat MCAO Models. 61
31293416 2019
32
Ganoderma sinense polysaccharide: An adjunctive drug used for cancer treatment. 61
31030747 2019
33
Ganoderma lucidum polysaccharide used for treating physical frailty in China. 61
31030748 2019
34
Gender differences in mental health and substance use disorders and related healthcare services utilization. 61
30536669 2019
35
Prevalence and Screening of Mental Illness among Remand Prisoners in Hong Kong. 61
30563950 2018
36
Severe hair loss associated with psychotropic drugs in psychiatric inpatients-Data from an observational pharmacovigilance program in German-speaking countries. 61
30193142 2018
37
Hallucination in Adolescence-Or, Nora in Nowhereland Between Neurosis and Psychosis. 61
30300083 2018
38
Effects of Antiparkinson Medication on Cognition in Parkinson's Disease: A Systematic Review. 61
29747716 2018
39
Simultaneous Determination of the Traditional Herbal Formula Ukgansan and the In Vitro Antioxidant Activity of Ferulic Acid as an Active Compound. 61
29986512 2018
40
The influence of level of spinal cord injury on adipose tissue and its relationship to inflammatory adipokines and cardiometabolic profiles. 61
28758566 2018
41
"The Neurosis That Has Possessed Us": Political Repression in the Cold War Medical Profession. 61
29718289 2018
42
Psychogenic voice disorders. 61
30190444 2018
43
Antipsychotic Prescribing and Safety Monitoring Practices in Children and Youth: A Population-Based Study in Alberta, Canada. 61
29453686 2018
44
The ethical dimension of analytical psychology. 61
29504686 2018
45
Massive GGAAs in genomic repetitive sequences serve as a nuclear reservoir of NF-κB. 61
29748061 2018
46
Social involvement issues in patients with Becker muscular dystrophy: A questionnaire survey of subjects from a patient registry. 61
29196072 2018
47
Specific agreement on ordinal and multiple nominal outcomes can be calculated for more than two raters. 61
29217452 2018
48
Yokukansan, a traditional Japanese herbal medicine, enhances the anxiolytic effect of fluvoxamine and reduces cortical 5-HT2A receptor expression in mice. 61
29382554 2018
49
A meta-analysis of the use of probiotics to alleviate depressive symptoms. 61
29197739 2018
50
[Lupus-like syndrome in patients treated with anti-TNF-α factors]. 61
30020046 2018

Variations for Neurotic Disorder

Expression for Neurotic Disorder

Search GEO for disease gene expression data for Neurotic Disorder.

Pathways for Neurotic Disorder

Pathways related to Neurotic Disorder according to KEGG:

36
# Name Kegg Source Accession
1 Neuroactive ligand-receptor interaction hsa04080
2 Dopaminergic synapse hsa04728

GO Terms for Neurotic Disorder

Biological processes related to Neurotic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to estradiol GO:0032355 9.54 TH SLC6A4 GPX4
2 vasoconstriction GO:0042310 9.4 SLC6A4 HTR1A
3 neurotransmitter biosynthetic process GO:0042136 9.32 TH SLC6A4
4 behavior GO:0007610 9.26 HTR2A HTR1A
5 positive regulation of lipopolysaccharide-mediated signaling pathway GO:0031666 9.16 LY96 LY86
6 serotonin receptor signaling pathway GO:0007210 8.96 HTR2A HTR1A
7 memory GO:0007613 8.92 TH SLC6A4 HTR2A BDNF

Molecular functions related to Neurotic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.89 TH SNRPD1 SLC6A4 PCDHB14 MAOA LY96
2 serotonin binding GO:0051378 8.8 SLC6A4 HTR2A HTR1A

Sources for Neurotic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....